By Karen Roman
NanoCell Therapeutics, Inc. said it published data in the Journal for ImmunoTherapy of Cancer showing the results of NCtx, its targeted lipid nanoparticle delivery system.
The study is the first successful demonstration of non-viral DNA delivery to T cells in the field of in vivo CAR-T cancer therapy, the company stated.
“We can potentially dramatically simplify treatment protocols while expanding access in the future to patients worldwide who currently cannot benefit from conventional CAR-T therapies,” said Dr. Jacek Lubelski, NanoCell Therapeutics CTO and senior author of the study.
READ MORE
ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
Never Miss our Weekly Highlights HERE
